Mesothelioma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight's, 'Mesothelioma Pipeline Insight 2025' report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Mesothelioma pipeline landscape. It covers the Mesothelioma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Mesothelioma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Mesothelioma Pipeline Outlook Report
Key Takeaways from the Mesothelioma Pipeline Report
In March 2025, Genmab initiated a Phase 1/2 study of Rina-S (GEN1184), a folate receptor alpha (FRα)-targeted antibody-drug conjugate, to evaluate its safety, tolerability, pharmacokinetics (PK), and antitumor activity in participants with selected locally advanced and/or metastatic solid tumors, including epithelial ovarian cancer, endometrial cancer, breast cancer, non-small cell lung cancer, and mesothelioma.
DelveInsight's Mesothelioma pipeline report depicts a robust space with 45+ active players working to develop 50+ pipeline therapies for Mesothelioma treatment.
The leading Mesothelioma Companies such as Polaris Pharmaceuticals, AstraZeneca, MedImmune LLC, Takeda, RS Oncology LLC, Vivace Therapeutics, Inc., VM Oncology, LLC, KaliVir Immunotherapeutics, UTC Therapeutics Inc., Tango Therapeutics, Inc., Verismo Therapeutics, SpringWorks Therapeutics, Inc., Gilead Sciences, Nurix Therapeutics, Inc., Amphera BV, Merck Sharp & Dohme LLC, Constellation Pharmaceuticals, BridGene Biosciences Inc., Aromics Therapeutics, and Ascentage Pharma Group Inc. and others.
Promising Mesothelioma Therapies such as Pembrolizumab, Lenvatinib, Nivolumab, Ipilimumab, ZD1839, Zometa, Durvalumab, and others.
Learn how leading Mesothelioma Companies are positioning themselves for success in the evolving pharmaceutical market—access the full report today!" @ Mesothelioma Clinical Trials Assessment
Mesothelioma Emerging Drugs
Pegargiminase: Polaris Pharmaceuticals
Pegargiminase (ADI‑PEG 20), is a biologic in late-stage clinical development for a wide range of cancers. It is a novel therapeutic protein being developed for cancers with a unique metabolic trait. Pegargiminase deprives the cancer cells of the amino acid Arginine by converting plasma-borne arginine into citrulline. At the core of their deficiency is a down-regulation of Argininosuccinate Synthase (ASS1), an enzyme needed to synthesize arginine. To survive, the cancer cells must 'rewire' their metabolism. This exerts a stress on the cells that renders them more susceptible to conventional chemotherapies. Pegargiminase has also gained Orphan Drug Designation for mesothelioma both in the U.S. and in Europe. Currently, the drug is in Preregistration stage of its development for the treatment of Mesothelioma.
Volrustomig: AstraZeneca
Volrustomig is an engineered Fragment Crystallizable (Fc) domain bispecific human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, volrustomig targets and binds to both PD-1 and CTLA4 expressed on tumor-infiltrating T lymphocytes (TILs), and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Mesothelioma.
Tremelimumab: MedImmune LLC
Tremelimumab is a type of monoclonal antibody and a type of immune checkpoint inhibitor. It is a drug that binds to the protein CTLA-4 to help immune cells kill cancer cells better and is used to treat different types of cancer. Tremelimumab is directed against cytotoxic T- lymphocyte-associated protein 4 (CTLA-4). By blocking the activity of CTLA-4, tremelimumab 'releases the brakes' on T cell activation and boosts the immune response against cancer cells. It is a fully human monoclonal antibody, which stimulates the immune system to destroy cancer cells through binding to the protein CTLA-4, expressed on the surface of activated T-lymphocytes. Tremelimumab has been granted Orphan Drug Designation and Fast Track Designation form the US Food and Drug Administration. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Mesothelioma.
TAK-500: Takeda
TAK-500 is a first-in-class STING agonist immunostimulatory antibody drug conjugate (iADC) that delivers dazostinag to CCR2+ myeloid cells in the tumor microenvironment. By targeting the STING pathway and CCR2 expressing myeloid cells, TAK-500 may offer enhanced potency via improved PK and selective delivery. TAK-500 has three possible mechanisms of action: activation of IFN response, reprogramming of suppressive intratumoral CCR2+ myeloid cells, and blockade of suppressive tumor-associated macrophage recruitment. Activation of STING leads to the production of proinflammatory cytokines that activate dendritic cells, macrophages, and natural killer cells, and subsequently mobilize adaptive immune cells against tumor cells. Combining TAK-500 with radiation and/or checkpoint inhibitors led to enhanced antitumor activity in preclinical studies. Dying tumor cells release tumor antigens and tumor-derived cGAMP, which continue to activate the STING pathway. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Mesothelioma.
RSO-021: RS Oncology LLC
RSO-021 is a naturally occurring, sulfur-rich, cyclic oligopeptide of the thiopeptide class, which covalently inactivates PRX3, leading to catastrophic oxidative stress and cell death. It is a novel first-in-class small molecule that irreversibly binds and inhibits mitochondrial peroxiredoxin 3 (PRX3). Inhibition of the PRX3 antioxidant signaling network in mitochondria results in selective killing of malignant cells by upregulation of oxidative stress; in contrast, healthy tissue is spared. In pre-clinical models RSO-021 reduces tumor growth in mice, sensitizes tumor cells to apoptosis and reduces the expression of pro-metastatic epithelial to mesenchymal (EMT) genes. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Mesothelioma.
The Mesothelioma Pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Mesothelioma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Mesothelioma Treatment.
Mesothelioma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Mesothelioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Mesothelioma market.
From early-stage research to late-phase Mesothelioma Clinical Trials, our analysis covers key Mesothelioma Companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don't miss this opportunity to stay informed—download now! @ Mesothelioma Treatment Drugs
Mesothelioma Companies
Polaris Pharmaceuticals, AstraZeneca, MedImmune LLC, Takeda, RS Oncology LLC, Vivace Therapeutics, Inc., VM Oncology, LLC, KaliVir Immunotherapeutics, UTC Therapeutics Inc., Tango Therapeutics, Inc., Verismo Therapeutics, SpringWorks Therapeutics, Inc., Gilead Sciences, Nurix Therapeutics, Inc., Amphera BV, Merck Sharp & Dohme LLC, Constellation Pharmaceuticals, BridGene Biosciences Inc., Aromics Therapeutics, and Ascentage Pharma Group Inc. and others.
Stay updated with the latest Mesothelioma Pipeline Insights—download our report for a deep dive into the next generation of therapeutics! @ Mesothelioma Market Drivers and Barriers, and Future Perspectives
Scope of the Mesothelioma Pipeline Report
Coverage- Global
Mesothelioma Companies- Polaris Pharmaceuticals, AstraZeneca, MedImmune LLC, Takeda, RS Oncology LLC, Vivace Therapeutics, Inc., VM Oncology, LLC, KaliVir Immunotherapeutics, UTC Therapeutics Inc., Tango Therapeutics, Inc., Verismo Therapeutics, SpringWorks Therapeutics, Inc., Gilead Sciences, Nurix Therapeutics, Inc., Amphera BV, Merck Sharp & Dohme LLC, Constellation Pharmaceuticals, BridGene Biosciences Inc., Aromics Therapeutics, and Ascentage Pharma Group Inc. and others
Mesothelioma Therapies- Pembrolizumab, Lenvatinib, Nivolumab, Ipilimumab, ZD1839, Zometa, Durvalumab, and others.
Mesothelioma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Mesothelioma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Find answers in our latest Mesothelioma Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!" @ Mesothelioma Emerging Drugs and Companies
Table of Content
Introduction
Executive Summary
Mesothelioma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Mesothelioma – DelveInsight's Analytical Perspective
Late Stage Products (Preregistration)
Pegargiminase: Polaris Pharmaceuticals
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Tremelimumab: MedImmune LLC
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
TAK-500: Takeda
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Mesothelioma Key Companies
Mesothelioma Key Products
Mesothelioma- Unmet Needs
Mesothelioma- Market Drivers and Barriers
Mesothelioma- Future Perspectives and Conclusion
Mesothelioma Analyst Views
Mesothelioma Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hernia-repair-devices-market
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 days ago
- Globe and Mail
Facial Lines Market Set for Significant Transformation by 2032, Forecasts DelveInsight
"Facial Lines Market" Facial Lines Companies working in the market are Ipsen, Evolus, Inc., and others. (Albany, USA) DelveInsight's ' Facial Lines - Market Insight, Epidemiology, And Market Forecast - 2032 ″ report offers an in-depth understanding of the Facial Lines, historical and forecasted epidemiology as well as the Facial Lines market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. The Facial Lines market is experiencing steady advancements, driven by evolving treatment approaches and research innovations. DelveInsight's latest 7MM report provides comprehensive insights into key epidemiology trends and market dynamics. Some of the key facts of the Facial Lines Market Report: According to DelveInsight, the market for Facial Lines in the 7MM is expected to grow steadily from 2019 to 2032. According to the Global Burden of Disease Study 2019, the global incidence of orofacial clefts decreased from 237,258 cases in 1990 to 192,708 cases in 2019, with an age-standardized rate (ASR) reduction from 3.61 per 100,000 in 1990 to 2.98 per 100,000 in 2019. Ultraviolet (UV) light and sunlight exposure significantly accelerate skin aging, resulting in photoaging, which is responsible for 90% of visible skin changes. The wrinkle scale, rated on a 0-9 scale, is a valuable tool in research for evaluating different types of aesthetic procedures. Emerging drugs for aesthetic treatments include IPN10200, PrabotulinumtoxinA-Xvfs, IncobotulinumtoxinA, and others. Leading companies in the aesthetic and dermatology market include Ipsen, Evolus, Inc., and others. Photoaging continues to be a significant factor in skin damage, driving the development of new treatments in the aesthetics industry. To Know in detail about the Facial Lines market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here: Facial Lines Market Forecast Facial Lines Overview Facial lines, commonly known as wrinkles, are visible creases or folds in the skin that develop due to aging, repetitive facial expressions, sun exposure, and other environmental and genetic factors. These lines can appear on different areas of the face, including the forehead, around the eyes (crow's feet), between the eyebrows (glabellar lines), and around the mouth (nasolabial folds and marionette lines). The primary cause of facial lines is the gradual decline in collagen and elastin production, which leads to reduced skin elasticity and firmness. Additionally, repeated muscle movements, such as frowning, smiling, or squinting, contribute to the formation of dynamic wrinkles, which may become static over time as the skin loses its ability to bounce back. External factors such as prolonged sun exposure, smoking, pollution, and poor skincare habits can accelerate the development of facial lines. While facial lines are a natural part of aging, various treatment options are available to minimize their appearance. These include topical treatments (retinoids, peptides, and hyaluronic acid-based creams), minimally invasive procedures (botulinum toxin injections, dermal fillers, and laser therapy), and more advanced interventions like chemical peels, microneedling, and facelift surgery. With increasing consumer demand for aesthetic procedures and advancements in dermatological treatments, the market for facial line reduction continues to grow, offering both preventive and corrective solutions to individuals seeking youthful, smoother skin. Facial Lines Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Facial Lines Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Facial Lines market or expected to be launched during the study period. The analysis covers the Facial Lines market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the activities of the facial lines pipeline development. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Facial Lines Market Strengths Growing consumer interest in non-invasive and minimally invasive cosmetic procedures, such as botulinum toxin injections and dermal fillers, is driving market expansion. Increasing social media influence and a focus on youthful appearances further fuel demand. Continuous improvements in anti-aging treatments, including next-generation fillers, laser therapies, and skincare formulations with peptides and hyaluronic acid, enhance treatment efficacy and patient satisfaction. Facial Lines Market Weaknesses Premium aesthetic procedures, such as laser resurfacing and high-end dermal fillers, can be expensive, limiting accessibility for a broader population, particularly in developing regions. Strict regulations on cosmetic injectables and emerging anti-aging treatments, along with concerns about side effects or complications, may hinder market growth and delay product approvals. Scope of the Facial Lines Market Report Study Period: 2019–2032 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Facial Lines Therapies: IPN10200, PrabotulinumtoxinA-Xvfs, IncobotulinumtoxinA, and others. Key Facial Lines Companies: Ipsen, Evolus, Inc., and others. Facial Lines Therapeutic Assessment: Facial Lines currently marketed and Facial Lines emerging therapies Facial Lines Market Dynamics: Facial Lines market drivers and Facial Lines market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Facial Lines Unmet Needs, KOL's views, Analyst's views, Facial Lines Market Access and Reimbursement To learn more about the key players and advancements in the Facial Lines Treatment Landscape, visit the Facial Lines Market Analysis Report Table of Contents 1. Facial Lines Market Report Introduction 2. Executive Summary for Facial Lines 3. SWOT analysis of Facial Lines 4. Facial Lines Patient Share (%) Overview at a Glance 5. Facial Lines Market Overview at a Glance 6. Facial Lines Disease Background and Overview 7. Facial Lines Epidemiology and Patient Population 8. Country-Specific Patient Population of Facial Lines 9. Facial Lines Current Treatment and Medical Practices 10. Facial Lines Unmet Needs 11. Facial Lines Emerging Therapies 12. Facial Lines Market Outlook 13. Country-Wise Facial Lines Market Analysis (2019–2032) 14. Facial Lines Market Access and Reimbursement of Therapies 15. Facial Lines Market Drivers 16. Facial Lines Market Barriers 17. Facial Lines Appendix 18. Facial Lines Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
Globe and Mail
02-06-2025
- Globe and Mail
Chronic Insomnia Market Growth Projections 2023-2032: DelveInsight Analysis
The Key Chronic Insomnia Companies in the market include - Janssen Research & Development, Takeda, and others. The Chronic Insomnia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Insomnia pipeline products will significantly revolutionize the Chronic Insomnia market dynamics. DelveInsight's 'Chronic Insomnia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chronic Insomnia, historical and forecasted epidemiology as well as the Chronic Insomnia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. Some of the key facts of the Chronic Insomnia Market Report: The Chronic Insomnia market size was valued ~USD 333 million in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032) Among the seven major markets (7MM), the United States represented 67.3% of the total market size for Chronic Insomnia in 2021. In the 7 MM countries, there will be 5,697,127 cases of chronic insomnia that have been diagnosed as of 2021 Age plays a significant role in how the disease develops. The age group of 20 to 29 years saw the highest number of cases in the US in 2021 with 474,746. Following this, there were 421,996 instances in the US for each of the age groups of 30-39 and 40-49 years France had the greatest diagnosed prevalence of chronic insomnia among the European nations, with 890,539 cases. Germany came in second with 407,108 cases in 2021 Germany reported 207,625 instances of chronic insomnia in females and 199,483 cases in men among the EU5 nations in 2021 Key Chronic Insomnia Companies: Janssen Research & Development, Takeda, and others Key Chronic Insomnia Therapies: Seltorexant, Ramelteon and zolpidem, and others The Chronic Insomnia epidemiology based on gender analyzed that Chronic Insomnia is more prominent in females in comparison to males The Chronic Insomnia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Insomnia pipeline products will significantly revolutionize the Chronic Insomnia market dynamics. Chronic Insomnia Overview Chronic insomnia is a long-term sleep disorder characterized by difficulty falling asleep, staying asleep, or waking up too early, occurring at least three times a week for three months or more. It leads to daytime fatigue, impaired concentration, mood disturbances, and reduced quality of life. Causes can include stress, medical conditions, medications, or poor sleep habits. Get a Free sample for the Chronic Insomnia Market Report: Chronic Insomnia Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Chronic Insomnia Epidemiology Segmentation: The Chronic Insomnia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: Total Prevalence of Chronic Insomnia Prevalent Cases of Chronic Insomnia by severity Gender-specific Prevalence of Chronic Insomnia Diagnosed Cases of Episodic and Chronic Chronic Insomnia Download the report to understand which factors are driving Chronic Insomnia epidemiology trends @ Chronic Insomnia Epidemiology Forecast Chronic Insomnia Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Insomnia market or expected to get launched during the study period. The analysis covers Chronic Insomnia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Chronic Insomnia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Chronic Insomnia Therapies and Key Companies Discover more about therapies set to grab major Chronic Insomnia market share @ Chronic Insomnia Treatment Market Chronic Insomnia Market Drivers Increasing Prevalence Personalization of therapies Chronic Insomnia Market Barriers Issues with diagnosis and poor knowledge Use of off-label drugs High economic burden Scope of the Chronic Insomnia Market Report Study Period: 2019–2032 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Chronic Insomnia Companies: Janssen Research & Development, Takeda, and others Key Chronic Insomnia Therapies: Seltorexant, Ramelteon and zolpidem, and others Chronic Insomnia Therapeutic Assessment: Chronic Insomnia current marketed and Chronic Insomnia emerging therapies Chronic Insomnia Market Dynamics: Chronic Insomnia market drivers and Chronic Insomnia market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Chronic Insomnia Unmet Needs, KOL's views, Analyst's views, Chronic Insomnia Market Access and Reimbursement Table of Contents 1. Chronic Insomnia Market Report Introduction 2. Executive Summary for Chronic Insomnia 3. SWOT analysis of Chronic Insomnia 4. Chronic Insomnia Patient Share (%) Overview at a Glance 5. Chronic Insomnia Market Overview at a Glance 6. Chronic Insomnia Disease Background and Overview 7. Chronic Insomnia Epidemiology and Patient Population 8. Country-Specific Patient Population of Chronic Insomnia 9. Chronic Insomnia Current Treatment and Medical Practices 10. Chronic Insomnia Unmet Needs 11. Chronic Insomnia Emerging Therapies 12. Chronic Insomnia Market Outlook 13. Country-Wise Chronic Insomnia Market Analysis (2019–2032) 14. Chronic Insomnia Market Access and Reimbursement of Therapies 15. Chronic Insomnia Market Drivers 16. Chronic Insomnia Market Barriers 17. Chronic Insomnia Appendix 18. Chronic Insomnia Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
29-05-2025
- Globe and Mail
Central Nervous System Tumors Pipeline Appears Robust With 13+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's ' Central Nervous System Tumors Pipeline Insight 2025 ' report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in Central Nervous System Tumors pipeline landscape. It covers the Central Nervous System Tumors pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Central Nervous System Tumors Pipeline. Dive into DelveInsight's comprehensive report today! @ Central Nervous System Tumors Pipeline Outlook Key Takeaways from the Central Nervous System Tumors Pipeline Report In May 2025, Genmab announced a study will be conducted in two parts: Part 1 (dose-finding) and Part 2 (randomization). The main purpose is to assess the safety and clinical activity of GEN1042 in combination with radiotherapy or GEN1042 in combination with radiotherapy and pembrolizumab as a treatment option for participants with metastatic solid tumors. In May 2025, Stemline Therapeutics Inc. announced a study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER-2) negative breast cancer. Phase 1b was designed to select the recommended phase 2 dose and is followed by an ongoing phase 2 evaluation of elacestrant in combination with abemaciclib in patients with active brain metastases from ER-positive, HER-2 negative breast cancer. In May 2025, Hoffmann-La Roche organized a study will evaluate the safety, pharmacokinetics, and efficacy of alectinib in children and adolescents with ALK fusion-positive solid or CNS tumors for whom prior treatment has proven to be ineffective or for whom there is no satisfactory standard treatment available. DelveInsight's Central Nervous System Tumors Pipeline report depicts a robust space with 13+ active players working to develop 13+ pipeline therapies for Central Nervous System Tumors treatment. Promising Central Nervous System Tumors Companies such as Shandong New Time Pharmaceutical, PIQUR Therapeutics, Ono Pharmaceutical, Janssen, LP, Kazia Therapeutics, Beijing InnoCare Pharma Tech, Celltrion, Bristol Myers Squibb, AstraZeneca, Novartis, Prelude Therapeutics, Kite, A Gilead Company, Celgene and others. The leading Central Nervous System Tumors Pipeline Therapies such as Tozuleristide, Bevacizumab, Temozolomide, Pomalidomide, Niraparib, GNC-038, Pamiparib, Thalidomide and others. Stay ahead with the most recent pipeline outlook for Central Nervous System Tumors. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Central Nervous System Tumors Treatment Drugs Central Nervous System Tumors Emerging Drugs Profile F520: Shandong New Time Pharmaceutical F 520 is a humanized monoclonal antibody targeting programmed cell death 1 receptor antagonists being developed by Shandong New Time Pharmaceutical. The drug is being investigated in Phase II stage of development for the treatment of patients with Primary and secondary Central Nervous System Lymphoma. Tirabrutinib: Ono Pharmaceuticals Velexbru, discovered and developed by ONO, is a highly selective, oral BTK inhibitor and has been developed for the treatment in patients with B-cell tumors and autoimmune diseases in Japan. B-cell receptor (BCR) signaling plays a core role in the survival, activation, proliferation, maturation and differentiation of B-cell lymphocyte. In Japan, Velexbru was approved in March 2020 and launched in May 2020 for the treatment of relapsed or refractory primary central nervous system lymphoma (PCNSL). Ono Pharmaceutical has initiated a Phase II clinical trial in US with Velexbru in patients with primary central nervous system lymphoma. The Central Nervous System Tumors Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Central Nervous System Tumors with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Central Nervous System Tumors Treatment. Central Nervous System Tumors Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Central Nervous System Tumors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Central Nervous System Tumors market Explore groundbreaking therapies and clinical trials in the Central Nervous System Tumors Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New Central Nervous System Tumors Drugs Central Nervous System Tumors Companies Shandong New Time Pharmaceutical, PIQUR Therapeutics, Ono Pharmaceutical, Janssen, LP, Kazia Therapeutics, Beijing InnoCare Pharma Tech, Celltrion, Bristol Myers Squibb, AstraZeneca, Novartis, Prelude Therapeutics, Kite, A Gilead Company, Celgene and others. Central Nervous System Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Parenteral Intravenous Subcutaneous Topical Molecule Type Central Nervous System Tumors Products have been categorized under various Molecule types such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Product Type Unveil the future of Central Nervous System Tumors Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Central Nervous System Tumors Market Drivers and Barriers Scope of the Central Nervous System Tumors Pipeline Report Coverage- Global Central Nervous System Tumors Companies- Shandong New Time Pharmaceutical, PIQUR Therapeutics, Ono Pharmaceutical, Janssen, LP, Kazia Therapeutics, Beijing InnoCare Pharma Tech, Celltrion, Bristol Myers Squibb, AstraZeneca, Novartis, Prelude Therapeutics, Kite, A Gilead Company, Celgene and others. Central Nervous System Tumors Pipeline Therapies- Tozuleristide, Bevacizumab, Temozolomide, Pomalidomide, Niraparib, GNC-038, Pamiparib, Thalidomide and others. Central Nervous System Tumors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Central Nervous System Tumors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Central Nervous System Tumors Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Central Nervous System Tumors Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary Central Nervous System Lymphoma: Overview Pipeline Therapeutics Therapeutic Assessment Late Stage Products (Phase III) Drug Name: Company Name Drug profiles in the detailed report….. Mid Stage Products (Phase II) F520: Shandong New Time Pharmaceutical Drug profiles in the detailed report….. Early stage products (Phase I) PRT811: Prelude Therapeutics Drug profiles in the detailed report….. Inactive Products Central Nervous System Lymphoma Key Companies Central Nervous System Lymphoma Key Products Central Nervous System Lymphoma- Unmet Needs Central Nervous System Lymphoma- Market Drivers and Barriers Central Nervous System Lymphoma- Future Perspectives and Conclusion Central Nervous System Lymphoma Analyst Views Central Nervous System Lymphoma Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
